MOZOBIL
Total Payments
$40.5M
Transactions
1,411
Doctors
459
Companies
3
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $31,323 | 16 | 15 |
| 2023 | $152,640 | 62 | 56 |
| 2022 | $9.1M | 127 | 79 |
| 2021 | $5.3M | 142 | 80 |
| 2020 | $5.5M | 87 | 48 |
| 2019 | $4.9M | 253 | 77 |
| 2018 | $3.9M | 287 | 81 |
| 2017 | $11.7M | 437 | 172 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $39.3M | 117 | 97.0% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $798,268 | 242 | 2.0% |
| Consulting Fee | $216,880 | 35 | 0.5% |
| Travel and Lodging | $105,631 | 275 | 0.3% |
| Space rental or facility fees (teaching hospital only) | $41,350 | 13 | 0.1% |
| Food and Beverage | $38,262 | 597 | 0.1% |
| Education | $11,024 | 132 | 0.0% |
Payments by Type
Research
$39.3M
117 transactions
General
$1.2M
1,294 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Phase 2 Study of Plerixafor and Cemiplimab in Metastatic Pancreatic Cancer. | GENZYME CORPORATION | $8.9M | 0 |
| A Phase I Study of Mozobil in the Treatment of Patients with the Primary Immunodeficiency WHIM Syndrome | SANOFI US SERVICES INC. | $5.9M | 0 |
| A Phase II follow-up study to determine whether the addition of whole brain radiotherapy (WBRT) to standard temozolomide chemo-radiotherapy will improve overall survival in patients with newly diagnos | SANOFI US SERVICES INC. | $5.1M | 0 |
| To Assess the Safety of Continuous IV Administration of the CXCR4 Antagonist, Plerixafor (Mozobil), and Assess Its Impact on the Immune Microenvironment in Patients With Advanced Pancreatic, High Grad | SANOFI US SERVICES INC. | $4.0M | 0 |
| A Phase III, Double-blind, Randomized, Crossover Study of Plerixafor Versus G-CSF in the Treatment of Patients with WHIM Syndrome | SANOFI US SERVICES INC. | $2.7M | 0 |
| A Phase 2 Study of Plerixafor and Cemiplimab in Metastatic Pancreatic Cancer. | SANOFI US SERVICES INC. | $2.1M | 0 |
| A Multi-center Randomized Phase II Study of the Impact of CD34+ Cell Dose on Progression-free Survival Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory | SANOFI US SERVICES INC. | $1.6M | 0 |
| Collaborative - A PROSPECTIVE, MULTICENTER, OBSERVATIONAL STUDY TO EVALUATE HEMATOPOIETIC PROGENITOR CELL MOBILIZATION IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA | GENZYME CORPORATION | $1.6M | 0 |
| A Multi-center Randomized Phase II Study of the Impact of CD34+ Cell Dose on Progression-free Survival Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL) | SANOFI US SERVICES INC. | $1.5M | 0 |
| Role of Mobilized Hematopoietic Stem Cells as Therapy in a Large Animal Model of Fulminant Hepatic Failure | SANOFI US SERVICES INC. | $1.3M | 0 |
| A Phase II followup study to determine whether the addition of whole brain radiotherapy (WBRT) to standard temozolomide chemoradiotherapy will improve overall survival in patients with newly diagnosed glioblastoma (GBM) treated with 4 weeks of continuous infusion Plerixafor | SANOFI US SERVICES INC. | $885,562 | 0 |
| A Phase II follow-up study to determine whether the addition of whole brain radiotherapy (WBRT) to standard temozolomide chemo-radiotherapy will improve overall survival in patients with newly diagnosed glioblastoma (GBM) | SANOFI US SERVICES INC. | $631,947 | 0 |
| Quantitating the Impact of Plerixafor Alone or in Combination with Bortezomib on Plasma Cell Mobilization and the Subsequent Impact on HLA Antibody Levels | SANOFI US SERVICES INC. | $527,607 | 0 |
| Peripheral blood stem cell collection for sickle cell disease patients | SANOFI US SERVICES INC. | $477,835 | 0 |
| A Multicenter Randomized Phase II Study of the Impact of CD34+ Cell Dose on Absolute Lymphocyte Count Following Highdose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large Bcell Lymphoma (DLBCL) | SANOFI US SERVICES INC. | $354,264 | 0 |
| A Multi-center Randomized Phase II Study of the Impact of CD34+ Cell Dose on Progression-free Survival Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL) | GENZYME CORPORATION | $318,173 | 0 |
| Quantitating the Impact of Plerixafor Alone or in Combination with Bortezomib on Plasma Cell Mobilization and the Subsequent Impact on HLA Antibody Levels | GENZYME CORPORATION | $251,821 | 0 |
| Safety and Efficacy Trial of Escalation of Plerixafor for Mobilization of CD34+ Hematopoietic Progenitor Cells and Evaluation of Globin Gene Transfer in Patients with Sickle Cell Disease | SANOFI US SERVICES INC. | $189,334 | 0 |
| A Phase II follow-up study to determine whether the addition of whole brain radiotherapy (WBRT) to standard temozolomide chemo-radiotherapy will improve overall survival in patients with newly diagnosed glioblastoma (GBM) treated with 4 weeks of continuous infusion Plerixafor | GENZYME CORPORATION | $175,500 | 0 |
| A Multi-center Randomized Phase II Study of the Impact of CD34+ Cell Dose on Absolute Lymphocyte Count Following High-dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL) | GENZYME CORPORATION | $140,371 | 0 |
Top Doctors Receiving Payments for MOZOBIL
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Phoenix, AZ | $39.4M | 144 |
| , M.D | Hematology & Oncology | San Antonio, TX | $144,496 | 64 |
| , MD | Hematology & Oncology | Milwaukee, WI | $114,752 | 93 |
| , MD | Internal Medicine | Orlando, FL | $113,329 | 111 |
| , M.D | Hematology & Oncology | Milwaukee, WI | $83,707 | 36 |
| Luciano Costa | Hematology & Oncology | Charleston, SC | $75,538 | 43 |
| , MD | Internal Medicine | Denver, CO | $61,430 | 39 |
| , M.D | Hematology & Oncology | Scottsdale, AZ | $58,347 | 36 |
| , MD | Hematology & Oncology | Milwaukee, WI | $49,369 | 25 |
| , M.D | Hematology | Philadelphia, PA | $41,610 | 24 |
| , M.D | Hematology | Scottsdale, AZ | $25,761 | 12 |
| , MD | Hematology & Oncology | New Orleans, LA | $25,677 | 24 |
| , MD | Internal Medicine | Nashville, TN | $20,327 | 14 |
| , MD | Internal Medicine | Charlotte, NC | $18,080 | 10 |
| , PA | Physician Assistant | Indianapolis, IN | $15,214 | 23 |
| , MD | Hematology | Tampa, FL | $14,882 | 6 |
| , M.D | Hematology & Oncology | Boston, MA | $14,580 | 2 |
| , MD | Internal Medicine | Cleveland, OH | $13,728 | 8 |
| Anuj Mahindra | — | La Jolla, CA | $13,579 | 12 |
| , MD | Hematology & Oncology | San Antonio, TX | $12,055 | 8 |
| , MD | Internal Medicine | Philadelphia, PA | $9,066 | 8 |
| , D.O | Internal Medicine | Omaha, NE | $8,820 | 8 |
| , M.D | Internal Medicine | Houston, TX | $8,762 | 7 |
| , M.D | Hematology & Oncology | Houston, TX | $8,760 | 9 |
| , M.D | Hematology & Oncology | New York, NY | $8,542 | 7 |
Ad
Manufacturing Companies
- SANOFI US SERVICES INC. $27.5M
- GENZYME CORPORATION $12.8M
- SANOFI-AVENTIS U.S. LLC $312,759
Product Information
- Type Drug
- Total Payments $40.5M
- Total Doctors 459
- Transactions 1,411
About MOZOBIL
MOZOBIL is a drug associated with $40.5M in payments to 459 healthcare providers, recorded across 1,411 transactions in the CMS Open Payments database. The primary manufacturer is SANOFI US SERVICES INC..
Payment data is available from 2017 to 2024. In 2024, $31,323 was paid across 16 transactions to 15 doctors.
The most common payment nature for MOZOBIL is "Unspecified" ($39.3M, 97.0% of total).
MOZOBIL is associated with 20 research studies, including "A Phase 2 Study of Plerixafor and Cemiplimab in Metastatic Pancreatic Cancer." ($8.9M).